Preoperative oral pentoxifylline in case of coronary artery bypass grafting with left ventricular dysfunction (ejection fraction equal to/less than 30%)

Most coronary artery bypass grafts are done by applying cardiopulmonary bypass, which usually induces unwanted inflammatory reactions and impairs the outcomes. In order to minimize the perilous response of cardiopulmonary bypass, pentoxifylline was getting used orally. In a prospective, placebo-cont...

Full description

Saved in:
Bibliographic Details
Published in:Anatolian journal of cardiology 2015, Vol.15 (12), p.1014-1019
Main Authors: Mansourian, Soheil, Bina, Payvand, Fehri, Arezoo, Karimi, Abbas Ali, Boroumand, Mohammad Ali, Abbasi, Kyomars
Format: Article
Language:English
Subjects:
Administration, Oral
Aged
Coronary Artery Bypass
Female
Humans
Male
Middle Aged
Myocardial Infarction - complications
Myocardial Infarction - therapy
Original Investigation
Pentoxifylline - administration & dosage
Preoperative Care
Prospective Studies
Stroke Volume
Treatment Outcome
Vasodilator Agents - administration & dosage
Ventricular Dysfunction, Left - complications
Ventricular Dysfunction, Left - therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Most coronary artery bypass grafts are done by applying cardiopulmonary bypass, which usually induces unwanted inflammatory reactions and impairs the outcomes. In order to minimize the perilous response of cardiopulmonary bypass, pentoxifylline was getting used orally. In a prospective, placebo-controlled, randomized clinical trial, 178 coronary artery bypass graft candidates with ejection fraction lower/equal to 30%, divided into two equal groups (pentoxifylline and control), participated in the study. Pentoxifylline patients received 400 mg pentoxifylline 3 times a day for 3 days before operation. The outcomes were compared between groups using student's t-test, Mann-Whitney U-test, Pearson chi-square, or Fisher's exact test. Pentoxifylline administration did not significantly affect troponin-T (p=0.68), but it reduced tumor necrosis factor-α (p=0.01) and interleukin-6 (p=0.01). It improved left ventricular ejection fraction significantly (p=0.01). White blood cell and platelet counts, hemoglobin, and hematocrit were not influenced by pentoxifylline. The drug did not affect blood urea nitrogen and creatinine, occurrence of renal failure, cerebrovascular accidents, and in-hospital mortality rate. The need for an intra-aortic balloon pump, cardiopulmonary bypass, and aortic cross-clamp times were not affected, either. Pentoxifylline decreased the intensive care unit stay (p
ISSN:2149-2263
2149-2271
DOI:10.5152/akd.2014.5883